Skip to main content

Tarlatamab Side Effects

Applies to tarlatamab: intravenous powder for injection.

Warning

Tell your medical caregivers if you have symptoms of a serious side effect, such as fever, chills, trouble breathing, vomiting, or severe tiredness.

Tarlatamab can also cause life-threatening nerve problems. Tell your caregivers or seek emergency medical attention if you have problems with speech, problems with thinking or memory, confusion, or a seizure.

Tarlatamab can increase your risk of serious bleeding. Stop using this medicine and call your doctor at once if you have severe stomach pain, bloody or tarry stools, coughing up blood, or any heavy or unusual bleeding.

Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.

For Healthcare Professionals

Applies to tarlatamab: intravenous powder for injection.

Hematologic

Very common (10% or more): Anemia (27%), decreased lymphocytes all grades (84%), decreased hemoglobin (58%), decreased white blood cells (44%), decreased platelets (33%), decreased neutrophils (12%)[Ref]

Immunologic

Very common (10% or more): Cytokine release syndrome (55%)[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (30%)[Ref]

Metabolic

Very common (10% or more): Hyponatremia (68%), decreased potassium (50%), decreased magnesium (33%), increased sodium (26%)[Ref]

Genitourinary

Very common (10% or more): Urinary tract infection (10%)[Ref]

Hepatic

Very common (10% or more): Increased hepatic enzymes: AST (44%), ALT (42%)

Respiratory

Very common (10% or more): Dyspnea (17%), cough (17%)

Common (1% to 10%): Pneumonia

Other

Very common (10% or more): Fatigue (51%), pyrexia (36%), decrease appetite (34%)[Ref]

General

The most common adverse events were cytokine release syndrome, fatigue, pyrexia, dysgeusia, decreased appetite and musculoskeletal pain.[Ref]

Nervous system

Very common (10% or more): Dysgeusia (36%)[Ref]

Renal

Very common (10% or more): Increased creatinine (29%)

Gastrointestinal

Very common (10% or more): Nausea (22%), constipation (30%)[Ref]

References

1. (2024) "Product Information. Imdelltra (tarlatamab)." Amgen USA

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.